Abramson JS et al. Lisocabtagene maraleucel (liso-cel) versus standard of care (SOC) with salvage chemotherapy followed by autologous stem cell transplantation (ASCT) as second-line (2L) treatment in patients with relapsed or refractory large B-cell lymphoma (LBCL): Primary analysis of the randomized, phase 3 Transform study. ASH 2022;Abstract 655.
Alderuccio JP et al. Loncastuximab tesirine in relapsed/refractory high-grade B-cell lymphoma: A subgroup analysis from the LOTIS-2 study. Blood Adv 2022;6(16):4736-9. Abstract
Bannerji R et al. Odronextamab, a human CD20×CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): Results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial. Lancet Haematol 2022;9(5):e327-39. Abstract
Ben Barouch S et al. Long-term follow up of relapsed/refractory non-Hodgkin lymphoma patients treated with single-agent selinexor – A retrospective, single center study. Leuk Lymphoma 2022;63(8):1879-86. Abstract
Bishop MR et al. Second-line tisagenlecleucel or standard care in aggressive B-cell lymphoma. N Engl J Med 2022;386(7):629-39. Abstract
Budde LE et al. Single-agent mosunetuzumab shows durable complete responses in patients with relapsed or refractory B-cell lymphomas: Phase I dose-escalation study. J Clin Oncol 2022;40(5)481-91. Abstract
Dickinson MJ et al. Glofitamab for relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med 2022;387(24):2220-31. Abstract
Falchi L et al. First-line treatment (tx) with subcutaneous (SC) epcoritamab (epco) + R-CHOP in patients (pts) with high-risk diffuse large B-cell lymphoma (DLBC): Phase 1/2 data update. J Clin Oncol 2022;40(16):7523. Abstract
Herrera AF et al. Risk profiling of patients with previously untreated diffuse large B-cell lymphoma (DLBCL) by measuring circulating tumor DNA (ctDNA): Results from the POLARIX study. ASH 2022;Abstract 542.
Kamdar M et al. Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSORM): Results from an interim analysis of an open-label, randomised, phase 3 trial. Lancet 2022;399(10343):2294-308. Abstract
Locke FL et al. Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma. N Engl J Med 2022;386(7):640-54. Abstract
Nowakoski GS et al. Improved efficacy of tafasitamab plus lenalidomide versus systemic therapies for relapsed/refractory DLBCL: RE-MIND2, an observational retrospective matched cohort study. Clin Cancer Res 2022;28(18):4003-17. Abstract
Sehn LH et al. Polatuzumab vedotin plus bendamustine and rituximab in relapsed/refractory DLBCL: Survival update and new extension cohort data. Blood Advances 2022;6(2):533-43. Abstract
Thieblemont C et al. A tumor volume and performance status model to predict outcome before treatment in diffuse large B-cell lymphoma. Blood Adv 2022;6(23):5995-6004. Abstract
Tilly H et al. Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma. N Engl J Med 2022;386(4):351-63. Abstract
Zijlstra JM et al. The association between patient characteristics and the efficacy and safety of selinexor in diffuse large B-cell lymphoma in the SADAL study. Cancers (Basel) 2022;14(3):791. Abstract